Literature DB >> 9271355

Interactions of the nonsedating antihistamine loratadine with a Kv1.5-type potassium channel cloned from human heart.

A E Lacerda1, M L Roy, E W Lewis, D Rampe.   

Abstract

The use of nonsedating antihistamines may, on rare occasions, be associated with cardiac arrhythmias. This could be due to blockade of voltage-dependent K+ channels in the heart, leading to a prolongation in repolarization in the human myocardium. For this reason, we examined the effects of the nonsedating antihistamine loratadine on a rapidly activating delayed-rectifier K+ channel (Kv1.5) cloned from human heart and stably expressed in HEK 293 cells or mouse Ltk- cells. Using patch-clamp electrophysiology, we found that loratadine blocked Kv1.5 current measured from inside-out membrane patches at concentrations of > or = 100 nM, resulting in an IC50 value of 808 nM at +50 mV. The drug enhanced the rate of Kv1.5 current decay, and block was enhanced at membrane potentials near threshold relative to higher potentials. Loratadine did not alter the kinetics of Kv1.5 current activation or deactivation. Unitary Kv1.5 currents were recorded in cell-attached patches. At the single-channel level, the main effect of loratadine was to reduce the mean probability of opening of Kv1.5. This effect of loratadine was achieved by a reduced number of openings in bursts and burst duration. Finally, loratadine (10 microM) failed to inhibit HERG K+ channel currents expressed in Xenopus laevis oocytes. It is concluded that loratadine is an effective blocker of Kv1.5 that interacts with an activated state or states of the channel. This interaction suggests a potential for loratadine to alter cardiac excitability in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9271355     DOI: 10.1124/mol.52.2.314

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  11 in total

Review 1.  Effects of H1 antihistamines on animal models of QTc prolongation.

Authors:  J Gras; J Llenas
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

2.  Cardiotoxicity of second-generation antihistamines.

Authors:  D J Roberts
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

3.  Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs.

Authors:  F J de Abajo; L A Rodríguez
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

4.  Rosiglitazone inhibits Kv4.3 potassium channels by open-channel block and acceleration of closed-state inactivation.

Authors:  I Jeong; B H Choi; S J Hahn
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

5.  Effects of lobeline, a nicotinic receptor ligand, on the cloned Kv1.5.

Authors:  Imju Jeong; Bok Hee Choi; Sang June Hahn
Journal:  Pflugers Arch       Date:  2010-08-24       Impact factor: 3.657

Review 6.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac kv1.5 channels.

Authors:  R Caballero; C Valenzuela; M Longobardo; J Tamargo; E Delpón
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

8.  Auranofin protects against anthrax lethal toxin-induced activation of the Nlrp1b inflammasome.

Authors:  Zachary L Newman; Nicole Sirianni; Christina Mawhinney; Margaret S Lee; Stephen H Leppla; Mahtab Moayeri; Lisa M Johansen
Journal:  Antimicrob Agents Chemother       Date:  2010-12-13       Impact factor: 5.191

9.  Identification of novel small molecule modulators of K2P18.1 two-pore potassium channel.

Authors:  J Kyle Bruner; Beiyan Zou; Hongkang Zhang; Yixin Zhang; Katharina Schmidt; Min Li
Journal:  Eur J Pharmacol       Date:  2014-06-24       Impact factor: 4.432

Review 10.  Safety of antihistamines in children.

Authors:  A P Ten Eick; J L Blumer; M D Reed
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.